Posts tagged RCH-01
RepliCel details go-forward strategy

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has formulated a strategic plan for 2017 through 2019 focused on maturing its assets through three distinct pillars.

Read More
RepliCel dermal injection device gets U.S. patent

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has received a key patent in the U.S. covering significant components of its novel, multi-needle dermal injection device. 

Read More
RepliCel hair loss trial meets primary endpoints

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness).

Read More
RepliCel receives two patents in Europe

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. 

Read More